Legend Biotech director receives 20,986 share units
One-third of the RSUs will vest on December 20, 2027, and the remainder in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Legend Biotech Corp (LEGN) director Tomas J. Heyman acquired 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings after the grant were 53,720 ordinary shares. The ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS representing two ordinary shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares F1, F2 | 20,986 | $0.00 | $0.00 |
Footnotes (2)
- F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
- F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
contingent right financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many RSUs did LEGN director Tomas J. Heyman acquire?
When do Tomas J. Heyman's LEGN RSUs vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.